AstraZeneca Wants Seroquel Antitrust Suits Moved to Delaware

AstraZeneca Pharmaceuticals LP says a federal court in Delaware, where its headquarters are, should hear a lawsuit consolidated in New York that claims it conspired to delay generic versions of its antipsychotic Seroquel XR.

The antitrust suit also targets Handa Pharmaceuticals LLC, Accord Healthcare Inc., and Endo International PLC subsidiary Par Pharmaceutical Inc. It challenges patent infringement settlements AstraZeneca reached with them after they sought approval for Seroquel generics. Seroquel, used to treat schizophrenia and bipolar disorder, has sales exceeding $1 billion a year.

In exchange for agreements by Handa and Accord to delay their generics until the expiration of ...